Alpha 2.0
Login Register
» Authors » P Koralewski

P Koralewski

Explore the profile of P Koralewski including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 19
Citations 694
Followers 0
Related Specialties
Oncology
General Medicine
Pharmacology
Top 10 Co-Authors
M Pawlicki
L Mauriac
J Rolski
J Zaluski
J Cassidy
J Bonneterre
C Szczylik
A Pluzanska
J McKendrick
C Bokemeyer
Published In
Ann Oncol
Wiad Lek
Przegl Lek
Ginekol Pol
Pneumonol Pol
Affiliations
Soon will be listed here.
Recent Articles
1.
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
Bokemeyer C, Bondarenko I, Hartmann J, de Braud F, Schuch G, Zubel A, et al.
Ann Oncol . 2011 Jan; 22(7):1535-1546. PMID: 21228335
Background: The randomized phase II OPUS (Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer) study showed that tumor KRAS mutation status was predictive for outcome in patients receiving...
2.
Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck
Mesia R, Rivera F, Kawecki A, Rottey S, Hitt R, Kienzer H, et al.
Ann Oncol . 2010 Mar; 21(10):1967-1973. PMID: 20335368
Background: A phase III trial demonstrated that cetuximab is the first agent in 30 years to improve survival when added to platinum-based chemotherapy (platinum-fluorouracil) first line for recurrent and/or metastatic...
3.
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer
Cunningham D, Sirohi B, Pluzanska A, Utracka-Hutka B, Zaluski J, Glynne-Jones R, et al.
Ann Oncol . 2008 Oct; 20(2):244-50. PMID: 18854549
Background: Oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) are standard first-line treatments for patients with metastatic colorectal cancer (mCRC). The aim of this multicentre, open-label, phase IIIb study was to assess...
4.
A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients
Pivot X, Koralewski P, Hidalgo J, Chan A, Goncalves A, Schwartsmann G, et al.
Ann Oncol . 2008 Apr; 19(9):1547-52. PMID: 18436520
Background: XRP6258 is a novel taxoid with a low affinity for P-glycoprotein. This multicenter phase II study assessed the activity of XRP6258 in the treatment of taxane-resistant metastatic breast cancer...
5.
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma
Melichar B, Koralewski P, Ravaud A, Pluzanska A, Bracarda S, Szczylik C, et al.
Ann Oncol . 2008 Apr; 19(8):1470-1476. PMID: 18408224
Background: In patients with untreated metastatic renal cell carcinoma (mRCC), progression-free survival (PFS) was longer with bevacizumab + interferon (IFN)-alpha than IFN + placebo (AVOREN trial). In this hypothesis-generating study,...
6.
Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase I study
Bonneterre J, Campone M, Koralewski P, Blasinska-Morawiec M, Deporte-Fety R, Chatelut E, et al.
Cancer Chemother Pharmacol . 2007 Jun; 60(3):365-73. PMID: 17569044
Purpose: The aim of this study was to investigate the combination of vinorelbine (VRL) alternating intravenous (i.v.) and oral in combination with docetaxel (DCT) as first-line chemotherapy of patients with...
7.
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial
Scheithauer W, McKendrick J, Begbie S, Borner M, Burns W, Burris H, et al.
Ann Oncol . 2003 Nov; 14(12):1735-43. PMID: 14630678
Background: Oral capecitabine achieves a superior response rate with an improved safety profile compared with bolus 5-fluorouracil-leucovorin (5-FU/LV) as first-line treatment for patients with metastatic colorectal cancer. We report here...
8.
Oral vinorelbine: feasibility and safety profile
Depierre A, Freyer G, Jassem J, Orfeuvre H, Ramlau R, Lemarie E, et al.
Ann Oncol . 2002 Feb; 12(12):1677-81. PMID: 11843244
Background: Patient preference as well as concerns and difficulties with intravenous access and pharmaco-economic issues have driven the development of oral vinorelbine. Patients And Methods: Four phase II studies were...
9.
Pharmacokinetics and toxicity of oral (-)-(S)-bromofosfamide in lung cancer patients
Kobylinska K, Koralewski P, Sobik B, Gasiorek M, Kobylinska M
Arzneimittelforschung . 2001 Aug; 51(7):600-3. PMID: 11505793
The pharmacokinetics and toxicity of (-)-(S)-bromofosfamide ((2S)-(2-chloroethylamino)-3-(2-bromoethyl)-1,3,2-oxazaphosphorinae 2-oxide, CAS 146452-37-1, CBM-11) were determined in ten patients with non-small cell lung cancer following an oral dose of 1.38 g/m2 B.S.A. (Body...
10.
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
Bonneterre J, Thurlimann B, Robertson J, Krzakowski M, Mauriac L, Koralewski P, et al.
J Clin Oncol . 2000 Nov; 18(22):3748-57. PMID: 11078487
Purpose: To compare the efficacy and tolerability of anastrozole (Arimidex; AstraZeneca, Wilmington, DE, and Macclesfield, United Kingdom) with that of tamoxifen as first-line therapy for advanced breast cancer (ABC) in...